209 related articles for article (PubMed ID: 35703246)
21. Associations between anemia and FGF23 in the CKiD study.
Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
[TBL] [Abstract][Full Text] [Related]
22. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
23. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
24. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism.
Courbon G; David V
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):368-374. PubMed ID: 38661434
[TBL] [Abstract][Full Text] [Related]
26. Inflammation regulates fibroblast growth factor 23 production.
Francis C; David V
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):325-32. PubMed ID: 27191351
[TBL] [Abstract][Full Text] [Related]
27. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
28. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
29. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
30. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
31. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
[TBL] [Abstract][Full Text] [Related]
32. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Li J; Xie QH; You L; Xu NX; Hao CM
Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
[TBL] [Abstract][Full Text] [Related]
33. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
34. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
36. Ironing out the cross talk between FGF23 and inflammation.
David V; Francis C; Babitt JL
Am J Physiol Renal Physiol; 2017 Jan; 312(1):F1-F8. PubMed ID: 27582104
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
38. Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.
Babitt JL; Sitara D
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):304-310. PubMed ID: 31145704
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
He J; Jia Z; Zhang A; Bai M
Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Aniort J; Greze C; Kosmadakis G
Nephrol Ther; 2022 Dec; 18(6S1):6S25-6S32. PubMed ID: 36585122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]